PROCEPT BioRobotics (PRCT)
(Delayed Data from NSDQ)
$49.96 USD
+1.45 (2.99%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $49.00 -0.96 (-1.92%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PRCT 49.96 +1.45(2.99%)
Will PRCT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PRCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRCT
Envoy Medical, Inc. (COCH) Reports Q2 Loss, Tops Revenue Estimates
Will PROCEPT BioRobotics Corporation (PRCT) Report Negative Earnings Next Week? What You Should Know
PRCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates
PROCEPT BioRobotics Corporation (PRCT) Reports Q4 Loss, Tops Revenue Estimates
Penumbra (PEN) Beats Q4 Earnings and Revenue Estimates
Other News for PRCT
Intel reports mixed Q2, FCC approves Skydance-Paramount deal: Morning Buzz
Procept BioRobotics (PRCT) Shares Drop Amid CEO Transition
Procept BioRobotics down after CEO retirement
What You Missed On Wall Street On Friday
PROCEPT BioRobotics Announces Leadership Transition and Strong Revenue Growth | PRCT stock news